Skip to main content

Neutrexin Side Effects

Generic name: trimetrexate

Note: This document contains side effect information about trimetrexate. Some dosage forms listed on this page may not apply to the brand name Neutrexin.

Applies to trimetrexate: intravenous powder for solution.

Warning

Intravenous routePowder for SolutionTrimetrexate glucuronate for injection must be used with concurrent leucovorin (leucovorin protection) to avoid potentially serious or life-threatening toxicities.

Trimetrexate glucuronate for injection must be used with concurrent leucovorin (leucovorin protection) to avoid potentially serious or life-threatening toxicities.

Serious side effects of Neutrexin

Along with its needed effects, trimetrexate (the active ingredient contained in Neutrexin) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking trimetrexate:

More common

Less common

Rare

Other side effects of Neutrexin

Some side effects of trimetrexate may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

Less common

For Healthcare Professionals

Applies to trimetrexate: intravenous powder for injection.

General

Because many patients in clinical trials had advanced HIV disease, it was difficult to distinguish between trimetrexate-associated side effects and underlying medical conditions. In a clinical trial, 10% of patients in the trimetrexate-leucovorin group discontinued treatment due to side effects, as compared to 29% in the sulfamethoxazole-trimethoprim group.[Ref]

Hematologic

Hematologic toxicity has been the primary dose-limiting adverse effect. In a clinical trial (n=109) trimetrexate (the active ingredient contained in Neutrexin) commonly caused myelosuppression, resulting in neutropenia (<= 1000/mm3) in 30%, thrombocytopenia (<=75,000/mm3) in 10%, and anemia (Hgb<8 g/dL) in 7% of patients also treated with leucovorin. Therapy was discontinued in 3.7% of patients due to hematologic toxicity.[Ref]

Renal

Renal toxicity consisting of elevations in serum creatinine greater than 3 times upper normal limits has occurred in 0.9% of clinical trial patients treated with trimetrexate (the active ingredient contained in Neutrexin) and leucovorin.[Ref]

Gastrointestinal

Gastrointestinal side effects associated with trimetrexate (the active ingredient contained in Neutrexin) have included nausea and vomiting in 5% or more of patients also treated with leucovorin. Mucositis and diarrhea also occur relatively often.[Ref]

Hepatic

Hepatic side effects have included transient elevations in liver function tests in up to 14% (n=109) of trial patients who also received leucovorin with increases greater than 5 times upper normal limits in AST (13.8%), ALT (11%), alkaline phosphatase (4.6%), and 2.5 times upper normal limit increases in bilirubin (1.8%). Discontinuation of therapy was necessary in approximately 3% of cases.[Ref]

Hypersensitivity

Hypersensitivity reactions to trimetrexate (the active ingredient contained in Neutrexin) have occurred and are generally limited to skin rash and pruritus. However, severe reactions consisting of bronchospasm, hypotension, rigors, and fever have occurred rarely.[Ref]

Respiratory

Respiratory side effects have included dyspnea and rare cases of pneumonitis.[Ref]

Metabolic

Metabolic abnormalities have included hyponatremia (4.6%) and hypocalcemia (1.8%).[Ref]

Dermatologic

Dermatologic side effects have included alopecia in a few patients treated with trimetrexate (the active ingredient contained in Neutrexin) [Ref]

Nervous system

Nervous system side effects have included confusion (2.8%) and fatigue (1.8%).[Ref]

References

1. Amsden GW, Kowalsky SF, Morse GD. Trimetrexate for Pneumocystis carinii pneumonia in patients with AIDS. Ann Pharmacother. 1992;26:218-26.

2. Product Information. NeuTrexin (trimetrexate). Apothecon Inc. 2022.

3. Gesme DH, Jr Jett JR, Schreffler DD, Su JQ, Mailliard JA, Foley JF, Krook JE, Maksymiuk AW, Hatfield AK, Ebbert LP, et al. A randomized phase II trial of amonafide or trimetrexate in patients with advanced non-small cell lung cancer. A trial of the North Central Cancer Treatment Group. Cancer. 1993;71:2723-6.

4. Weiss GR, Liu PY, O'Sullivan J, Alberts DS, Brown TD, Neefe JR, Hutchins LF. A randomized phase II trial of trimetrexate or didemnin B for the treatment of metastatic or recurrent squamous carcinoma of the uterine cervix: a Southwest Oncology Group trial. Gynecol Oncol. 1992;45:303-6.

5. Witte RS, Elson P, Bryan GT, Trump DL. Trimetrexate in advanced renal cell carcinoma. An ECOG phase II trial. Invest New Drugs. 1992;10:51-4.

6. Fossella FV, Winn RJ, Holoye PY, Hallinan B, Raber MN, Hoelzer K, Young JA, Readling J, Bowers B, Hong WK. Phase II trial of trimetrexate for unresectable or metastatic non- small cell bronchogenic carcinoma. Invest New Drugs. 1992;10:331-5.

7. Conti JA, Kemeny N, Goker E, Tong W, Colofiore J, Andre M, Ragusa K, Bertino JR. A Phase I trial of sequential trimetrexate (TMTX), fluorouracil (FU) and high-dose leucovorin (LV) in previously treated patients (pts) with gastrointestinal (GI) carcinoma (Ca) (Meeting abstract). Proc Annu Meet Am Soc Clin Oncol. 1993;12:a567.

8. Hum M, Holcenberg JS, Tkaczewski I, Weaver JW, Wilson J, Kamen BA. High-dose trimetrexate and minimal-dose leucovorin: a case for selective protection? Clin Cancer Res. 1998;4:2981-4.

9. Allegra CJ, Chabner BA, Tuazon CU, et al. Trimetrexate for the treatment of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. N Engl J Med. 1987;317:978-85.

10. Grem JL, King SA, Costanza ME, Brown TD. Hypersensitivity reactions to trimetrexate. Invest New Drugs. 1990;8:211-4.

11. King SA, Grem JL. Acute allergic reactions to trimetrexate (TMTX) (meeting abstract). Proc Annu Meet Am Soc Clin Oncol. 1988;7:a284.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.